American Association for Cancer Research
10780432ccr180959-sup-199186_3_supp_5173845_prgpxr.png (1.31 MB)

Supplementary Figure 6 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis

Download (1.31 MB)
posted on 2023-03-31, 21:31 authored by Dongqing Yan, Anthony D. Pomicter, Srinivas Tantravahi, Clinton C. Mason, Anna V. Senina, Jonathan M. Ahmann, Qiang Wang, Hein Than, Ami B. Patel, William L. Heaton, Anna M. Eiring, Phillip M. Clair, Kevin C. Gantz, Hannah M. Redwine, Sabina I. Swierczek, Brayden J. Halverson, Erkan Baloglu, Sharon Shacham, Jamshid S. Khorashad, Todd W. Kelley, Mohamed E. Salama, Rodney R. Miles, Kenneth M. Boucher, Josef T. Prchal, Thomas O'Hare, Michael W. Deininger

Supplementary Figure 6






Myelofibrosis is a hematopoietic stem cell neoplasm characterized by bone marrow reticulin fibrosis, extramedullary hematopoiesis, and frequent transformation to acute myeloid leukemia. Constitutive activation of JAK/STAT signaling through mutations in JAK2, CALR, or MPL is central to myelofibrosis pathogenesis. JAK inhibitors such as ruxolitinib reduce symptoms and improve quality of life, but are not curative and do not prevent leukemic transformation, defining a need to identify better therapeutic targets in myelofibrosis. A short hairpin RNA library screening was performed on JAK2V617F-mutant HEL cells. Nuclear–cytoplasmic transport (NCT) genes including RAN and RANBP2 were among top candidates. JAK2V617F-mutant cell lines, human primary myelofibrosis CD34+ cells, and a retroviral JAK2V617F-driven myeloproliferative neoplasms mouse model were used to determine the effects of inhibiting NCT with selective inhibitors of nuclear export compounds KPT-330 (selinexor) or KPT-8602 (eltanexor). JAK2V617F-mutant HEL, SET-2, and HEL cells resistant to JAK inhibition are exquisitely sensitive to RAN knockdown or pharmacologic inhibition by KPT-330 or KPT-8602. Inhibition of NCT selectively decreased viable cells and colony formation by myelofibrosis compared with cord blood CD34+ cells and enhanced ruxolitinib-mediated growth inhibition and apoptosis, both in newly diagnosed and ruxolitinib-exposed myelofibrosis cells. Inhibition of NCT in myelofibrosis CD34+ cells led to nuclear accumulation of p53. KPT-330 in combination with ruxolitinib-normalized white blood cells, hematocrit, spleen size, and architecture, and selectively reduced JAK2V617F-mutant cells in vivo. Our data implicate NCT as a potential therapeutic target in myelofibrosis and provide a rationale for clinical evaluation in ruxolitinib-exposed patients with myelofibrosis.

Usage metrics

    Clinical Cancer Research